GM-CSFRα Inhibitors
GM-CSFRα inhibitors encompass a range of chemicals that act through various mechanisms to indirectly inhibit the activity of the Granulocyte-Macrophage Colony-Stimulating Factor Receptor alpha. These inhibitors target key components of signaling pathways that are downstream or associated with GM-CSFRα. For instance, inhibitors of the JAK/STAT pathway, such as Ruxolitinib and Fludarabine, can disrupt the primary signaling mechanism activated by GM-CSFRα, leading to reduced functional responses typically mediated by this receptor. Additionally, inhibitors of other signaling molecules and pathways, such as PI3K, mTOR, MEK, Src kinases, and NF-κB, also play significant roles in the modulation of GM-CSFRα activity. Compounds like Wortmannin, Rapamycin, Trametinib, Dasatinib, and BAY 11-7082, by targeting these pathways, indirectly influence the cellular processes governed by GM-CSFRα, including cell proliferation, survival, and differentiation. The inhibition of these pathways results in a decrease in the cellular responses that are usually activated following GM-CSFRα engagement.
Furthermore, inhibitors of protein kinases and other enzymes that are crucial in the downstream signaling of GM-CSFRα, such as Imatinib, 17-AAG, U0126, SB203580, and BMS-345541, contribute to the indirect modulation of GM-CSFRα activity. By targeting these kinases and enzymes, these inhibitors can lead to a reduction in the signaling cascade initiated by GM-CSFRα, ultimately affecting the receptor's role in various physiological and pathological processes. In summary, GM-CSFRα inhibitors comprise a diverse array of chemicals that act by indirectly modulating the signaling pathways associated with GM-CSFRα. Their mechanisms of action reflect the complex interplay between various signaling molecules and pathways in controlling the cellular responses mediated by GM-CSFRα. Understanding the role of these inhibitors not only provides insights into the regulation of GM-CSFRα but also highlights the avenues for inhibiting key physiological processes influenced by this receptor.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib is an inhibitor of Janus kinase (JAK) proteins, which play a crucial role in the signaling pathway downstream of GM-CSFRα. By inhibiting JAK, Ruxolitinib can reduce the downstream signaling, potentially leading to the reduced activity of GM-CSFRα-mediated pathways. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a phosphoinositide 3-kinase (PI3K) inhibitor. PI3K is part of the signaling cascade activated by GM-CSFRα. Inhibiting PI3K can disrupt this cascade, potentially reducing the effects mediated by GM-CSFRα activation. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is a MEK inhibitor, which can affect the MAPK/ERK pathway. Since the MAPK pathway is involved in cell proliferation and survival signals downstream of various cytokine receptors including GM-CSFRα, inhibiting this pathway might indirectly reduce GM-CSFRα-mediated cellular responses. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor, impacting cell growth and proliferation pathways. mTOR pathways can be downstream of GM-CSFRα signaling, and their inhibition may indirectly reduce the effects of GM-CSFRα activation. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib inhibits Src family kinases, which are involved in various signaling pathways including those related to cytokine receptor signaling. By inhibiting these kinases, Dasatinib could indirectly inhibit GM-CSFRα signaling pathways. | ||||||
Fludarabine | 21679-14-1 | sc-204755 sc-204755A | 5 mg 25 mg | $58.00 $204.00 | 15 | |
Fludarabine is a nucleotide analog that can inhibit STAT activation, a downstream component of GM-CSFRα signaling. Inhibiting STAT may lead to reduced transcriptional activity following GM-CSFRα activation. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 inhibits NF-κB, a transcription factor that can be activated downstream of GM-CSFRα. Inhibiting NF-κB might reduce the expression of genes regulated in response to GM-CSFRα activation. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor with activity against BCR-ABL and c-KIT. As tyrosine kinase signaling is crucial in GM-CSFRα pathways, its inhibition can indirectly affect GM-CSFRα-related responses. | ||||||
17-AAG | 75747-14-7 | sc-200641 sc-200641A | 1 mg 5 mg | $67.00 $156.00 | 16 | |
17-AAG inhibits Heat Shock Protein 90 (HSP90), a chaperone involved in stabilizing various proteins including kinases in GM-CSFRα signaling pathways. Inhibiting HSP90 might destabilize these kinases, thereby reducing GM-CSFRα signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 specifically inhibits p38 MAPK, a kinase involved in the cellular response to stress and cytokines. Inhibiting p38 MAPK might indirectly reduce GM-CSFRα-mediated effects. | ||||||